SASema Aydoğdu

Sema Aydoğdu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sema Aydoğdu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CMV Infection in Pediatric Liver Transplantation and Comparison of Prophylaxis Methods Depending on Donor Serostatus

    by Barut Dogan, Kunay Bora, Yildirim Arslan Sema, Umman Veysel, Dernek Benan, Kıran Taşçı Ezgi, Akkus Kayali Gozde, Sahbudak Bal, Aydogdu Sema, Cetin Funda, et al.

    Background/Aims: Cytomegalovirus (CMV) infection is a significant complication in pediatric liver transplant recipients. This study aimed to assess the incidence, risk factors, and suspected effects of CMV infection in children undergoing liver transplantation and compared acyclovir and ganciclovir-based preventive therapy. Materials and Methods: The study included 92 patients who had liver transplants at Ege University Transplantation Unit between 2011 and 2021. Sixty-four pediatric patients with preoperative CMV immunoglobulin G (IgG) positivity were analyzed. Patients with early mortality, re-transplantation within 6 months, and CMV IgG negativity were excluded. Results: The study consisted of 39 females (61%) and 25 males (39%), with a median age of 5.3 years at transplantation. Cytomegalovirus viremia occurred in 42 patients (65%), and CMV disease developed in 7 patients (10%). The median duration of CMV viremia was 40 days, and CMV disease was 105 days. Age was significantly associated with CMV disease development, with younger patients at higher risk (P = .007). The choice of antiviral treatment (acyclovir vs. valganciclovir) did not significantly impact the development of CMV vire mia or disease. Conclusion: Cytomegalovirus viremia and disease are common in pediatric liver transplant recipients, with younger age being a signifi cant risk factor for CMV disease. However, CMV viremia and disease did not significantly impact this cohort’s graft loss, acute cellular rejection, or mortality. The choice of antiviral treatment and immunosuppression protocols did not influence CMV outcomes. These find ings highlight the need for vigilant monitoring and tailored management strategies for CMV in pediatric liver transplantation. Cite this article as: Dogan B, Bora K, Sema YA, et al. CMV infection in pediatric liver transplantation and comparison of prophylaxis methods depending on donor serostatus. Turk J Gastroenterol. Published online November 7, 2025. doi:10.5152/tjg.2025.24585.

  • Open Access

    Author Correction to: “Disseminated cryptococcosis in a child with liver transplantation: a case report.” [Turk J Pediatr 2024; 66: 499-504.]

    by Doğan Barut, Bora Kunay, Sema Yıldırım Arslan, Ayça Aydın Uysal, Zümrüt Şahbudak Bal, Pınar Yazıcı, Miray Karakoyun, Sema Aydoğdu

  • Open Access

    Disseminated cryptococcosis in a child with liver transplantation: a case report

    by Doğan Barut, Bora Kunay, Sema Yıldırım Arslan, Gözde Kayalı Akkuş, Zümrüt Şahbudak Bal, Pınar Yazıcı, Miray Karakoyun, Sema Aydoğdu

    Background. Cryptococcus neoformans causes cryptococcosis, primarily affecting immunocompromised individuals, including solid-organ transplant recipients, and, less frequently, immunocompetent people. Case. A 15-year-old male with congenital hepatic fibrosis, portal hypertension, and cirrhosis underwent orthotopic liver transplantation. He received perioperative antimicrobial and antifungal prophylaxis and continued immunosuppressive treatment. Thirty months post-transplant, he presented with fever, hypertension, and sacroiliac joint pain. Peripheral blood cultures showed C. neoformans, confirmed by pan-fungal polymerase chain reaction assay and latex agglutination tests. Despite initial treatment with intravenous (IV) fluconazole, his condition worsened, necessitating intubation for acute hypoxic respiratory failure. Magnetic resonance imaging and computed tomography scans indicated disseminated cryptococcosis with lymphadenitis, possible meningitis, and pneumonia. Treatment was escalated to IV liposomal amphotericin B and 5-flucytosine, while reducing immunosuppressive treatment. Despite negative fungal cultures on the tenth day, the patient deteriorated, developing pancreatitis, pneumonia, and massive gastrointestinal bleeding, leading to death on the 35th day of hospitalization. Conclusion. This case shows the severity and complexity of managing disseminated cryptococcosis in pediatric liver transplant recipients. Aggressive therapy and early identification are essential for improving outcomes in these high-risk patients.


  • Open Access

    Transient Elastography for Noninvasive Evaluation of Posttransplant Liver Graft Fibrosis in Turkish Children, Ege University Children Hospital Experience

    by Barut Dogan, Bora Kunay, Veysel Umman, Ezgi Kıran Taşçı, Ziya Kumcuoğlu, Fatih Gulbahar, Deniz Nart, Miray Karakoyun, Funda Cetin, Sema Aydogdu

    Objectives: The influence of advancing fibrosis on graft survival in the context of pediatric liver transplantation accentuates the critical role of protocol‐driven liver biopsies, a practice adopted by numerous medical centers. Consequently, the exigency for noninvasive methodologies to assess graft fibrosis assumes heightened importance when conventional clinical and laboratory parameters fail to reveal signs of liver damage.Methods: This study aimed to assess the reliability of transient elastography (TE) in pediatric liver transplant recipients to detect graft fibrosis and compare the results of TE in patients who underwent biopsy.Results: This prospective cohort study included liver transplanted children who underwent biopsy at Ege University Children's Hospital between October 1, 2021, and October 31, 2022, and a healthy control group. According to TE, fibrosis was detected in 40 patients, and no fibrosis was detected in 50. The median time to develop fibrosis was 100 months (95% CI [83.1–116.8]). A statistically significant positive correlation existed between LSM and METAVIR fibrosis score (r = 0.562, p = 0.001). There was a statistically significant difference in LSM between patients with F2 fibrosis (7.8–8.8 kPa ± 3.2) compared to patients with F0 fibrosis (5.2 kPa ± 0.7) (p = 0.005) and F1 fibrosis (6.1 kPa ± 1.5) (p = 0.041), on ANOVA.Conclusion: Liver allograft fibrosis is common in long‐term follow‐up in children who have undergone liver transplantation. Abnormal TE may guide physicians to consider liver biopsy to detect late allograft fibrosis in these children.

  • Open Access

    Post‐transplant lymphoproliferative disorder associated Epstein‐Barr virus DNAemia after liver transplantation in children: Experience from single center

    by Barut Dogan, Yildirim Arslan Sema, Kunay Bora, Umman Veysel, Dernek Benan, Kıran Taşçı Ezgi, Akkus Kayali Gozde, Derya Demir, Nazan Ozsan, Mine Hekimgil, et al.

    The most prevalent malignancy that complicates both adult and pediatric solid organ transplantation is post‐transplant lymphoproliferative disorder (PTLD). This study aimed to analyze the clinical and pathological characteristics, treatments, and outcomes of Epstein‐Barr virus (EBV) DNAemia and PTLD in pediatric liver transplant recipients. A retrospective chart review was performed on 112 patients less than 18 years of age who underwent isolated orthotopic liver transplantation (OLT) between 2010 and 2022 at Ege University Children's Hospital. Data gathered for 1‐year post‐OLT included age at OLT, EBV, immunoglobulin (Ig)M/IgG status of the donor and recipient, indication for OLT, induction regimen, all immunosuppression levels, date and result of EBV polymerase chain reaction testing, rejection episodes documented by liver biopsy, and the development of PTLD. Forty‐nine patients (43.75%) developed EBV DNAemia (median interval from surgery: 2 months, min–max: 2–36), of which 43 (87.8%) grafts came from living donors, and 6 (12.2%) came from deceased donors. Nine (18.4%) patients died during follow‐up, and eight (16.3%) developed PTLD. Of these 8 patients; five patients developed EBV‐related disease, one child developed hemophagocytic lymphohistiocytosis, one developed aplastic anemia, and one child developed B cell lymphoma. When PTLD patients and without‐PTLD patients were compared, pediatric intensive care unit hospitalization, abnormal bone marrow biopsy findings, lymphadenopathy, age at diagnosis of EBV DNAemia, EBV viral load, tacrolimus (FK 506) pre‐infection, were higher and tacrolimus 1‐month levels were lower in patients with PTLD ( p < 0.05). In logistic regression analysis, we showed that the age at diagnosis of EBV DNAemia was significantly higher in children with PTLD ( p = 0.045; OR: 1.389; 95% CI: 1.007–1.914). PTLD is a rare but severe complication associated with EBV after OLT. This study demonstrated that PTLD is associated with older age, higher tacrolimus blood levels before EBV DNAemia, and higher peak EBV viral load at 1 month of EBV DNAemia.